2021
Patterns of Care for Older Patients With Myelofibrosis: A Population-based Study
Meckstroth S, Wang R, Ma X, Podoltsev N. Patterns of Care for Older Patients With Myelofibrosis: A Population-based Study. Clinical Lymphoma Myeloma & Leukemia 2021, 21: e551-e558. PMID: 33648884, DOI: 10.1016/j.clml.2021.01.025.Peer-Reviewed Original ResearchConceptsPatterns of careOlder patientsEnd Results-Medicare databaseJAK inhibitor eraHigh-risk patientsPopulation-based studyUse of ruxolitinibJAK inhibitor ruxolitinibUnited States FoodRuxolitinib approvalMedian ageMedian timeTreatment patternsD claimsCurrent treatmentInhibitor ruxolitinibPatientsBetter outcomesClinical experienceDrug AdministrationMedicare Part BMyelofibrosisRuxolitinibStates FoodNew drugsEpidemiology of the Philadelphia Chromosome-Negative Classical Myeloproliferative Neoplasms
Shallis RM, Zeidan AM, Wang R, Podoltsev NA. Epidemiology of the Philadelphia Chromosome-Negative Classical Myeloproliferative Neoplasms. Hematology/Oncology Clinics Of North America 2021, 35: 177-189. PMID: 33641862, DOI: 10.1016/j.hoc.2020.11.005.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsMeSH KeywordsHumansMaleMyeloproliferative DisordersPhiladelphia ChromosomePolycythemia VeraPrimary MyelofibrosisThrombocythemia, Essential
2020
Interferon Therapy in Myelofibrosis: Systematic Review and Meta-analysis
Bewersdorf JP, Giri S, Wang R, Podoltsev N, Williams RT, Rampal RK, Tallman MS, Zeidan AM, Stahl M. Interferon Therapy in Myelofibrosis: Systematic Review and Meta-analysis. Clinical Lymphoma Myeloma & Leukemia 2020, 20: e712-e723. PMID: 32669244, PMCID: PMC7541411, DOI: 10.1016/j.clml.2020.05.018.Peer-Reviewed Original ResearchConceptsOverall response rateTreatment of myelofibrosisPEG-IFNMF patientsResponse rateHematologic responseSystematic reviewFormulations of interferonPartial hematologic responseCochrane Central RegisterComplete hematologic responseRisk of progressionRole of interferonAcute myeloid leukemiaPhiladelphia chromosome-negative myeloproliferative neoplasmsRandom-effects modelBone marrow failureWeb of ScienceTreatment discontinuationCentral RegisterConstitutional symptomsHematologic improvementInterferon therapyAdverse eventsComplete responseLifestyle factors and risk of myeloproliferative neoplasms in the NIH‐AARP diet and health study
Podoltsev NA, Wang X, Wang R, Hofmann JN, Liao LM, Zeidan AM, Mesa R, Ma X. Lifestyle factors and risk of myeloproliferative neoplasms in the NIH‐AARP diet and health study. International Journal Of Cancer 2020, 147: 948-957. PMID: 31904114, PMCID: PMC8919268, DOI: 10.1002/ijc.32853.Peer-Reviewed Original ResearchConceptsNIH-AARP DietPolycythemia veraMyeloproliferative neoplasmsEssential thrombocythemiaHazard ratioLifestyle factorsCaffeine intakeHealth StudyMultivariable Cox proportional hazards regression modelsCox proportional hazards regression modelRisk of PVProportional hazards regression modelsRisk of MPNLarge prospective studiesHazards regression modelsConfidence intervalsPhiladelphia chromosome-negative myeloproliferative neoplasmsMPN riskOverall cohortProspective cohortProspective studyInverse associationRisk factorsPV riskProtective effect